Related posts
Tech and oil decline3 Popular Stocks of the Year, Part 1Wall Street advances, Bay Street pausesThis summary was created by AI, based on 2 opinions in the last 12 months.
BioNTech (BNTX-Q) is a German pharma company with a market cap of $24 billion. The company has received approvals to continue advancement into a new uterine cancer treatment and is progressing well. It trades at 8x trailing earnings, 1.1x book and supports a 23% ROE. Cash reserves are growing, while stock is being bought back. The stock has an upside potential of 31%, with analysts' price target at $137.07. However, there is no dividend yield for this stock.
Provides the key insight into mRNA that underlies the Covid vaccine. The mRNA technology can be developed into therapies that are targeted and safe. They are working on a flu vaccine as well as a cancer vaccine. Their pipeline is vast and the coronavirus vaccine is giving a huge cash hoard to pay for R&D. (Analysts’ price target is $185.00)
BioNTech is a American stock, trading under the symbol BNTX-Q on the NASDAQ (BNTX). It is usually referred to as NASDAQ:BNTX or BNTX-Q
In the last year, 1 stock analyst published opinions about BNTX-Q. 1 analyst recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for BioNTech.
BioNTech was recommended as a Top Pick by on . Read the latest stock experts ratings for BioNTech.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
1 stock analyst on Stockchase covered BioNTech In the last year. It is a trending stock that is worth watching.
On 2024-11-22, BioNTech (BNTX-Q) stock closed at a price of $113.13.
Our PAST TOP PICK with BNTX is progressing well. To remain disciplined, we recommend trailing up the stop (from $78) to $95 at this time.